Vigabatrin-associated brain abnormalities on MRI and other neurological symptoms in patients with West syndrome.

Gabriela Reyes Valenzuela, Agustina Crespo, Juan Princich, Lorena Fassulo, Marco Semprino, Adolfo Gallo, Carlos Rugilo, Juan Pociecha, Agustin Calvo, Roberto H Caraballo

Epilepsy & behavior : E&B 2022 Apr

filter terms:

Report a series of children with West syndrome (WS) treated with vigabatrin (VGB) who developed characteristic MRI alterations. In the majority, these adverse events were asymptomatic; however, some of the patients developed movement disorders and acute encephalopathy. This is a retrospective analysis of our epilepsy clinical and EEG database of 288 patients with WS seen between 2014 and 2020. All patients who received VGB alone or with concomitant therapies, such as adrenocorticotropic hormone (ACTH), high-dose oral corticosteroids, ketogenic diet, valproate, levetiracetam, or topiramate, were evaluated. In 44 of 288 patients with WS receiving VGB, MRI findings compatible with VGB-associated brain abnormalities were identified; median age at diagnosis was 6.29 months (range, 2 weeks to 11 months). The etiology of WS with vigabatrin-associated brain abnormalities on MRI (VABAM) was unknown in 22 (52.27%), genetic in seven (15.9%), genetic-structural in three (6.8%), structural malformative in three others (6.8%), and structural acquired in eight patients (18.2%). Vigabatrin-associated brain abnormalities on MRI was asymptomatic in 25 of 44 patients. Ten of 44 (22.7%) infants were reported to have had a movement disorder (choreoathetosis, dystonic posturing). Nine of 42 infants exhibited progressive psychomotor deterioration associated with signs and symptoms of encephalopathy. MRI abnormalities were observed in infants treated with VGB and they appeared to be dose dependent. In our study common locations for MRI abnormalities included globi pallidi and brainstem, followed by thalami and dentate nuclei. Risk factors for the development of VABAM may include age younger than 11 months and higher VGB dose of VGB (>165 mg/kg/day). Vigabatrin-associated brain abnormalities on MRI usually resolved following VGB discontinuation, probably after a period of 3 months. Copyright © 2022 Elsevier Inc. All rights reserved.

Citation

Gabriela Reyes Valenzuela, Agustina Crespo, Juan Princich, Lorena Fassulo, Marco Semprino, Adolfo Gallo, Carlos Rugilo, Juan Pociecha, Agustin Calvo, Roberto H Caraballo. Vigabatrin-associated brain abnormalities on MRI and other neurological symptoms in patients with West syndrome. Epilepsy & behavior : E&B. 2022 Apr;129:108606